AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
Separately, ValuEngine downgraded shares of AEterna Zentaris from a “sell” rating to a “strong sell” rating in a research report on Monday, September 17th. One equities research analyst has rated the stock with a sell rating and three have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $3.25.
Shares of NASDAQ:AEZS opened at $2.37 on Monday. The company has a market cap of $36.66 million, a PE ratio of 74.33 and a beta of 0.75. AEterna Zentaris has a twelve month low of $1.12 and a twelve month high of $3.25.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings data on Thursday, August 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.16. The business had revenue of $0.17 million during the quarter. AEterna Zentaris had a net margin of 6.76% and a return on equity of 20.71%. As a group, research analysts expect that AEterna Zentaris will post 0.05 earnings per share for the current fiscal year.
About AEterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.
Featured Story: What is Compound Interest?
Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.